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Abstract
Background: Violacein is a deep violet compound that is produced by a number of bacterial species. It is synthesized
from tryptophan by a pathway that involves the sequential action of 5 different enzymes (encoded by genes vioA to
vioE). Violacein has antibacterial, antiparasitic, and antiviral activities, and also has the potential of inducing apoptosis in
certain cancer cells.
Results: Here, we describe the construction of a series of plasmids harboring the complete or partial violacein
biosynthesis operon and their use to enable production of violacein and deoxyviolacein in E.coli. We performed
in vitro assays to determine the biological activity of these compounds against Plasmodium, Trypanosoma, and
mammalian cells. We found that, while deoxyviolacein has a lower activity against parasites than violacein, its
toxicity to mammalian cells is insignificant compared to that of violacein.
Conclusions: We constructed E. coli strains capable of producing biologically active violacein and related compounds,
and propose that deoxyviolacein might be a useful starting compound for the development of antiparasite drugs.
Keywords: Violacein, Deoxyviolacein, Plasmodium falciparum, Trypanosoma cruzi, Synthetic operon, Antiparasitic,
Escherichia coli
Background
Violacein is a violet indolocarbazole pigment that is pro-
duced by bacteria such as Chromobacterium violaceum,
which are commonly found in water and soil throughout
the world [1–6]. Violacein has antipyretic [7, 8], ulcer-
protective [8], antibacterial [9–11], antifungal [3, 12],
trypanocidal [13, 14], antileishmanial [15], antinematode
[16], and antiviral [17] activities. It also has the potential
of inducing apoptosis in certain cancer cells [2, 18]. Vio-
lacein kills wild-type and drug-resistant strains of the
malaria parasite, Plasmodium falciparum and is thera-
peutically against malaria in mice [19]. These character-
istics suggest that violacein has considerable research
potential and may represent a chemical scaffold for the
developemt of clinically useful drugs.
Commercially, violacein is usually isolated from Chro-
mobacterium [20–22] or Janthinobacterium [23, 24];
however, this process is costly and there are reports of
rare but deadly infections caused by these bacteria [25–
28]. Hence, there has been considerable interest in the
development of safe, and efficient routes to the biosyn-
thesis of this compound [1, 29–34].
The violacein biosynthetic pathway from L-tryptophan
(Fig. 1) requires the expression of five genes: vioA, vioB,
vioC, vioD, and vioE [35–39]. It should be noted that
VioC enzyme is involved in both the production of
deoxyviolacien from protodeoxyviolaceinic acid and in
the generation of violacein from protoviolaceinic acid.
Several studies have shown that transforming and ex-
pressing a complete metabolic pathway into a different
bacterial host may lead to improved production of viola-
cein [40–43]. For example, Rodrigues and co-workers
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[32–34] have successfully engineered Escherichia coli to
produce high yields of violacein and the side-product
deoxyviolacein. This was accomplished by cloning the
complete vioABCDE and the partial vioABCE operons (re-
spectively) from C. violaceum into pBADMycHisB, which
allows the induction of the operon by L-arabinose [32,
34]. These authors also metabolically engineered the host’s
tryptophan production to maximize the yield of violacein
and deoxyviolacein [32, 34, 42]. More recently Jones and
co-workers [44] and Xu and co-workers [45] utilized vio-
lacein biosynthesis as a model for metabolic pathway bal-
ancing and optimization. Employing different approaches,
they fine-tuned the expression of violacein-producing en-
zymes, leading to an improvement in the production of
the compound by up to 30-fold when compared to previ-
ously reported work.
We have generated a synthetic operon containing the
coding sequences of each of the five genes required for vio-
lacein biosynthesis, with a codon-usage optimized for E. coli
(http://parts.igem.org/Part:BBa_K274002). We also con-
structed strains lacking vioD, to promote the accumulation
of deoxyviolacein. A similar approach was employed by Ro-
drigues and co-workers for the production of high yields of
violacein and deoxyviolacein [32–34]. We produced and
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Fig. 1 Violacein biosynthetic pathway (a) and plasmid maps of the complete (b) and partial (c, d and e) operons for violacein biosynthesis
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purified violacein and deoxyviolacein, and characterized
their toxicity and antiplasmodial activity in wild-type and
drug-resistant Plasmodium falciparum strains; we also de-
termined their activity against Trypanosoma cruzi.
Methods
Bacterial strains and plasmids
We constructed plasmids expressing violacein and deoxy-
violacein by sub-cloning the synthetic violacein operon
(Part: BBa_K274002) designed by Shuna Gould for the
iGEM09_Cambridge project (http://parts.igem.org/Part:B-
Ba_K274002). The synthetic violacein operon is comprised
of the 5 coding sequences specifying violacein pathway en-
zymes (vioA, vioB, vioC, vioD and vioE), each preceded by
a ribosome-binding site. The operon was designed with a
BamHI site in the space between vioB and vioC open
reading-frames (ORFs), a BglII site between the vioC and
vioD ORFs, and a BclI site between the vioD and vioE
reading-frames. Since cleavage of the BamHI, BglII, and
BclI sites generate compatible cohesive ends, this facili-
tated the construction of three different operons:
vioABCE; vioABDE; vioABE. The synthetic operons are
flanked by EcoRI and PstI restriction endonuclease
sites, enabling the use of these two enzymes to readily
subclone the entire (vioABCDE) and partial operons
(vioABCE, vioABDE, vioABE) into the EcoRI and NsiI
sites of pBAT4 (Fig. 1).
Production and purification of violacein and deoxyviolacein
We transformed E. coli BL21(DE3) (New England Bio-
labs) cells with plasmids expressing the synthetic
vioABCDE (for production of both violacein and deoxy-
violaein) or vioABCE (for production of deoxyviolacein
alone) operons. The leaky expression from the T7 pro-
moter in these plasmids was enough to allow sufficient
synthesis of the enzymes in the violacein biosynthetic
pathway.
We picked individual colonies, inoculated 50 mL cul-
tures in 2× YT (16 g/L Tryptone, 10 g/L yeast extract,
5 g/L sodium chloride) with 100 mg/L ampicillin, and
incubated for 16 h at 37 °C. These pre-cultures were in-
oculated into 20 L of 2xYT supplemented with 100 mg/L
of ampicillin and 100 mg/L of L-tryptophan in a Sartor-
ius Biostat Cplus fermenter. Cultures were grown for 5 h
at 37 °C, with agitation (400 rpm) and air influx of 4 L/
min. The temperature was then reduced to 20 °C (to
avoid excessive growth and foaming overnight) and the
cultures were incubated for a further 16 h. Cells were
harvested by centrifugation. Violacein and deoxyviola-
cein were extracted by resuspending the bacterial pellets
in 500 mL of 90% v/v acetone. Cell suspensions in acet-
one were filtered to produce crude violacein and deoxy-
violacein extracts.
Violacein and deoxyviolacein purification
Deoxyviolacein
The acetone cell extract was evaporated to dryness. The
crude residue was suspended in acetone and dry-loaded
onto silica gel (SiO2). Deoxyviolacein was purified by
column chromatography on silica gel (SiO2), first wash-
ing with petroleum ether (boiling point = 40–60 °C) and
eluting with a 1:1 solution of ethyl acetate and petrol-
eum ether. Deoxyviolacein was obtained as a purple
solid and was analytically pure (100%). The identity and
purity of deoxyviolacein were confirmed by 1H NMR
(Additional file 1: Figure S1). We calculated the purity
by integrating related peaks and comparing the areas.
No other analysis was run because the data is consistent
with that from the literature [46]. The apparent purity of
deoxyviolacein allowed its quantitation and that of viola-
cein (see below). Minor contamination by inorganic
compounds cannot be excluded but these would need to
be soluble in acetone.
Violacein
The acetone cell extract was evaporated to dryness. The
crude residue was suspended in acetone with sonication
and dry-loaded onto silica gel (SiO2). Violacein was puri-
fied by column chromatography on silica gel (SiO2), first
washing with petroleum ether (boiling point = 40–60 °C)
and eluting with 4:6, 1:1, and 6:4 solutions of ethyl acet-
ate and petroleum ether (boiling point = 40–60 °C).
Violacein was obtained as a crude mixture with approxi-
mately 12% deoxyviolacein (estimated from 1H NMR).
The identity of violacein was confirmed by 1H NMR
(Additional file 1: Figure S1) and was consistent with the
literature [46].
Plasmodium falciparum drug sensitivity assays
We cultivated Plasmodium falciparum 3D7 and W2
strains in complete RPMI (RPMI 1640, Sigma, USA),
supplemented with 10% plasma (AB−) and 2% Haemato-
crit (O+). Plasmodium cultures were synchronized twice
with sorbitol, and drug sensitivity tests were performed
on cultures enriched for ring-stage parasites. The para-
sitemia of the cultures was adjusted to 1% and drug sen-
sitivity screens were performed in 96-well plates, with
the following drug concentrations: for violacein and
chloroquine [47] 8 concentrations of a 2× serial dilution,
starting with 5 μM were employed; for deoxyviolacein,
the same number of serial dilutions were tested with a
starting concentration of 50 μM. All experiments were
performed in triplicate and included solvent controls as
well as untreated erythrocytes. After 48 h of incubation
at 37 °C, cultures were labeled with SYBR® Green and
analyzed by flow cytometry. IC50s were calculated using
GraphPad Prism version 5.01.
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Trypanosoma cruzi drug sensitivity assays
In vitro drug sensitivity assays on Trypanosoma cruzi
were performed as described by Ferreira [48]. Briefly, we
performed the assays using T. cruzi strain Tulahuen
(parasites engineered to express E. coli β-galactosidase,
lacZ [49], that catalyzes a colorimetric reaction when
biologically active). Trypomastigotes were grown on
monolayers of human fibroblasts, and epimastigotes
were grown in liver infusion tryptone with 10% fetal
calf serum, penicillin and streptomycin (to prevent
contamination). Cultures assayed for β-galactosidase
activity were grown in RPMI 1640 medium without
phenol red plus 10% fetal calf serum, penicillin, and
streptomycin.
Drug-sensitivity assays were performed in 96-well tis-
sue culture plates (Becton Dickinson). Human fibro-
blasts were seeded at 2 × 103 per well in 80 μL volumes
(RPMI 1640 without phenol red) and incubated over-
night. The next day, β–galactosidase-expressing trypo-
mastigotes were added at 1 × 104 per well in 20 μL of
RPMI 1640 without phenol red. After 24 h, violacein or
deoxyviolacein (10 mM stocks in DMSO) were added to
the cultures in serial dilutions in 50 μL volumes (RPMI
1640 without phenol red). Each dilution was tested in
triplicate. After 72 h of incubation, the plates were
inspected under an inverted microscope to check the
growth of the controls and sterility. Then, 50 μL of the
substrate containing chlorophenol red-β-D-galactopyra-
noside (CPRG) and Nonidet P-40 (0.1% final concentra-
tion) was added to all wells. β–galactosidase activity led
to a change in the color of the medium from yellow to
red, a change that was quantified through measuring the
absorbance at 570 nm in an automated plate reader [48].
Wells containing violacein and deoxyviolacein (without
phenol red) were used to normalize for the purple color
of the compounds. Data were transferred into Sigma
Plot to determine IC50 values. The drug benzimidazole
was used as a positive control and untreated parasite
cultures were used as negative control for these assays.
Cytotoxicity of violacein and deoxyviolacein
The cytotoxicity of the compounds used in this work was
evaluated using an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay. MTT is a yellow tetra-
zole compound that is reduced to a purple formazan in
the mitochondria of living cells. Hence, the proportion of
living eukaryotic cells in a given culture can be quantified
by monitoring its absorbance at 590 nm.
We cultured HepG2 (human hepatoma) and COS-7
(kidney from African Green Monkey) cell lines in the
presence of different concentrations of the test com-
pounds, to evaluate their cytotoxicity. We incubated 104
cells in 200 μL cultures (96-well plates) in 5% v/v CO2 at
37 °C, in RPMI with Gentamicin (40 mg/L), and 10% of
heat-inactivated fetal calf serum (FCS). The final concen-
trations of test compounds were: violacein (10 μM,
5 μM, 2.5 μM, 1.25 μM and 0.62 μM) and deoxyviola-
cein (200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM).
After 48 of incubation, we added 15 μL of 5 mg/L
MTT and incubated for 4 h in 5% v/v CO2 at 37 °C. The
plate was then centrifuged at 1500 rpm for 5 min, the
supernatant discarded, the cells washed with PBS, and
resuspended in 50 μL of isopropanol. Wells containing
violacein and deoxyviolacein (without MTT) were used
to normalize for the purple color and precipitation of
the compounds.
We cultured HepG2 (human hepatoma) and CHO-745
(Chinese hamster ovary) cell lines in the presence of dif-
ferent concentrations of the test compounds, to evaluate
their morphology. We incubated 104 cells in 200 μL cul-
tures (96-well plates) in 5% v/v CO2 at 37 °C, in RPMI
with Gentamicin (40 mg/L), and 10% of heat-inactivated
fetal calf serum (FCS). The final concentrations of test
compounds were: violacein (0 μM, 0.8 μM, 4 μM, 20 μM
and 100 μM) and deoxyviolacein (0 μM, 0.8 μM, 4 μM,
20 μM and 100 μM).
Results
Activity of purified violacein and deoxyviolacein against
T. cruzi
We evaluated the biological activity of violacein and deox-
yviolacein produced in our recombinant E. coli strains ex-
pressing the complete or partial synthetic violacein
operon, and found that violacein could efficiently inhibit
the trypanosomatids, with an IC50 of 1.51 μM± 0.4,
whereas the IC50 for deoxyviolacein was above 50 uM. As
a comparison, the IC50 determined in the same experi-
ment for the anti T. cruzi drug benzimidazole (N-benzyl-
2-(2-nitro-1H- imidazol-1-yl)acetamide) was 3.07 μM
±0.6. The IC50 values of the compounds against the T.
cruzi Tulahuen strain in the in vitro assay represent the
means of at least three individual experiments.
Antiplasmodial activity of purified violacein and
deoxyviolacein
Initially, we tested higher concentrations (> 5 μM) of
violacein in a Plasmodium sensitivity test, and noted that
samples treated with 10 or 50 μM of violacein could not
be analyzed through flow cytometry as all erythrocytes
ruptured in the presence of those doses of the com-
pound. Violacein was active against both chloroquine-
sensitive and chloroquine-resistant Plasmodium strains
(IC50 ~ 0.4 μM against 3D7 and ~ 0.5 μM against W2
parasites). Deoxyviolacein, on the other hand, showed a
mild activity against Plasmodium strains when compared
with violacein (IC50 ~ 11 μM against 3D7 and ~ 14 μM
against W2 parasites). The chloroquine control curve
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performed in both strains showed IC50 values compar-
able with those described in the literature (Fig. 2).
Cytotoxicity of violacein and deoxyviolacein
When performing drug sensitivity assays on erythrocytes
infected with P.falciparum, we noticed that healthy and
infected erythrocytes ruptured when treated with 10 μM
or more of violacein. In contrast, erythrocytes treated
with 50 μM deoxyviolacein did not show any obvious
morphological changes compared to the untreated cells.
We evaluated the morphological changes in HepG2 and
CHO-745 cells upon exposure to violacein and deoxy-
violacein, but once more detected no morphological
changes to cells treated with 20 μM deoxyviolacein and
minor changes to cells treated with 100 μM deoxyviola-
cein (Additional file 2: Figures. S2 and S3).
We performed viability assays to investigate the tox-
icity of violacein and deoxyviolacein to COS-7 and
HepG2 cell lines. Our experiments confirmed the cytoxi-
city of violacein against both cell lines (IC50 of ~ 2.5 μM
against COS-7 and ~ 1.4 μM against HepG2), with a
stronger effect on the tumor cell line. In contrast, deoxy-
violacein showed low toxicity against mammalian cell
lines, as cells were able to grow well even in the pres-
ence of concentrations of deoxyviolacein 20 times higher
then its IC50 in Plasmodium strains (Fig. 3). We were
unable to test higher deoxyviolacein concentrations since
it precipitated under our experimental conditions.
Discussion
We have constructed E. coli strains producing either a
mixture of violacein or dexyviolacein alone, using enzymes
encoded by synthetic operons. The biological activity of
these compounds against Trypanosoma, Plasmodium and
mammalian cells was assessed. The synthesis of these pig-
ment compounds was easily monitored by their color and
it was possible to observe, for example, that pigment for-
mation was greatly enhanced by intense aeration.
We purified deoxyviolacein using the conditions de-
scribed in the Methods section, achieving close to 100%
purity in just a few purification steps. Violacein, how-
ever, was contaminated with approximately 12% deoxy-
violacein. Hence, in all experiments where we describe
the biological effects of violacein, we had some deoxy-
violacein as a contaminant. As the biological activity of
deoxyviolacein was consistently lower than that of viola-
cein, we inferred that this contamination would not
interfere with the interpretation of the results.
We performed in vitro assays to investigate the antiplas-
modial activity of violacein and deoxyviolacein, using both
3D7 (wild-type) and W2 (chloroquine-resistant) Plasmo-
dium falciparum strains. We found that the IC50 of viola-
cein was ca. 0.5 μM, whereas that of deoxyviolacein was
Fig. 2 Plasmodium falciparum growth inhibition assays. a IC50 3D7-
Violacein: 0.54 μM ±0.08; Deoxyviolacein: 11 μM ±0.1; Chloroquine:
18 nM ±0.1. b IC50 W2- Violacein: 0.42 μM ±0.14; Deoxyviolacein:
14.04 μM ±0.07; Chloroquine: 0.54 μM ±0.11
Fig. 3 Cytotoxicity of violacein and deoxyviolacein. MTT assay used
to investigate the cytotoxicity of violacein and deoxyviolacein to (a)
COS-7 and (b) HepG2 cells, indicated that deoxyviolacein shows no
measurable toxicity to mammalian cells, whereas the IC50 for
violacein is approximately 2.5 μM and 1.4 μM for COS-7 and HepG2
cells, respectively
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ca. 10 μM. The 3D7 and W2 strains were equally sensitive
to violacein and deoxyviolacein, whilst 3D7 was around 30
times more sensitive to chloroquine (IC50 ~ 20 nM) than
W2 (IC50 ~ 0.5uM). Hence, the mechanism conferring re-
sistance to chloroquine in W2 lines did not affect their
sensitivity to violacein or deoxyviolacein.
When treating Plasmodium-infected erythrocytes with
violacein, we found that higher concentrations of the pig-
ment caused the complete rupture of the red blood cells.
Hence, we decided to investigate the cytotoxicity of viola-
cein and deoxyviolacein. In spite of their very similar
structure, violacein was very toxic to mammalian cells,
whereas deoxyviolacein showed selective toxicity against
Plasmodium (the parasite was at least 20× more sensitive
to this compound than were the mammalian cells) than
violacein (the parasite showing only ca. 5× greater sensi-
tivity to this compound than did mammalian cells). The
IC50 of violacein produced from our synthetic operon is
about ~ 1.4 μM for HepG2 and ~ 2.5 μM for COS-7 cell
lines, in agreement with published results, indicating a de-
gree of specificity of the compound against cancer cells.
On the other hand, the HepG2 cell line showed no signifi-
cant viability loss when treated with deoxyviolacein con-
centrations close to 200 μM. When treating the
Trypanosoma cruzi Tulahuen strain with violacein and
deoxyviolacein, we also observed much higher biological
activity with violacein (IC50 of 1.51 μM± 0.4) than with
deoxyviolacein (IC50 > 50 μM).
Conclusions
We have utilized synthetic operons encoding enzymes
for complete or partial pathways for the biosynthesis of
violacein or deoxyviolacein in E. coli strains, and investi-
gated the biological activity of the produsts. Deoxyviola-
cein, in spite of its lower antiparasitic activity, might be
a better starting point than violacein for the develop-
ment of a novel antiparasitic drug due to its low toxicity
to human cells. However, it is important to note that we
did not investigate the import of either compound by
the target cells, and so cannot exclude the possibility
that deoxyviolacein’s lower toxicity was due to an ineffi-
cient import into mammalian or parasite cells.
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